Arrowhead Pharmaceuticals (NasdaqGS:ARWR) 2025 Conference November 19, 2025 06:00 AM ET Company ParticipantsChristopher Anzalone - CEOConference Call ParticipantsMaury Raycroft - AnalystMaury RaycroftHi, everyone. My name is Maury Raycroft. I'm one of the biotech analysts at Jefferies. I'd like to welcome Chris Anzalone, the CEO of Arrowhead. Thanks so much for joining us today, Chris, and congrats on the FCS approval yesterday.Christopher AnzaloneThanks very much. It's a pleasure to be here, as always, and ...

PresentationGood afternoon, and welcome to the Arrowhead Pharmaceuticals REDEMPLO FDA Approval Conference Call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Arrowhead website following the conclusion of the event. I'd now like to turn the call over to Vince Anzalone, Vice President of Finance and Investor Relations at Arrowhead Pharmaceuticals. Please go ahead, Vince.Vincent AnzaloneHead of Investor Relations & VP Thank you, Tara, and thank y ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Today, we take a look at Arrowhead Pharmaceuticals, Inc. ( ARWR ), who celebrated a transformational milestone on November 18 th with the approval of their lead drug candidate REDEMPLO™ (previously Plozasiran). REDEMPLO™ isI have a background in Risk Management, Finance, and Engineering and I write about what interests me. I hope you find it helpful - comments and questions are welcome.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no pl ...

Today, we take a look at Arrowhead Pharmaceuticals, Inc. ( ARWR ), who celebrated a transformational milestone on November 18 th with the approval of their lead drug candidate REDEMPLO™ (previously Plozasiran). REDEMPLO™ isI have a background in Risk Management, Finance, and Engineering and I write about what interests me. I hope you find it helpful - comments and questions are welcome.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no pl ...

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Update / Briefing November 18, 2025 01:30 PM ET Company ParticipantsAvi Novick - Biotech Equity Research AssociateJames Hamilton - Chief Medical Officer and Head of R&DAndy Davis - SVP and Head of Global Cardiometabolic FranchiseVince Anzalone - VP of Finance and Investor RelationsPeyton Bhonsack - VP of Biotechnology Equity ResearchPrakhar Agrawal - Managing DirectorBruce Given - Interim Chief Medical ScientistMorgan Lamberti - Equity Research AssociateChristopher ...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 ti. ...

The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals' drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the health regulator's websit... ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Arrowhead Pharmaceuticals ( ARWR ) has a busy schedule in the next few weeks. The PDUFA d ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Arrowhead Pharmaceuticals ( ARWR ) has a busy schedule in the next few weeks. The PDUFA d ...